From f8c9646f021ec905ec84234809560314e2e95a3a Mon Sep 17 00:00:00 2001 From: will king Date: Tue, 15 Oct 2024 17:03:28 -0700 Subject: [PATCH] minor changes --- Latex/Paper/sections/01_introduction.tex | 2 +- Latex/Paper/sections/05_LitReview.tex | 5 ++++- 2 files changed, 5 insertions(+), 2 deletions(-) diff --git a/Latex/Paper/sections/01_introduction.tex b/Latex/Paper/sections/01_introduction.tex index 6375efd..f72b0a9 100644 --- a/Latex/Paper/sections/01_introduction.tex +++ b/Latex/Paper/sections/01_introduction.tex @@ -78,7 +78,7 @@ The author states in his conclusion: From this we see that there was a cascade of issues leading to the failure to develop this novel drug. -Knowing how to separate + diff --git a/Latex/Paper/sections/05_LitReview.tex b/Latex/Paper/sections/05_LitReview.tex index 97ea175..066dd7d 100644 --- a/Latex/Paper/sections/05_LitReview.tex +++ b/Latex/Paper/sections/05_LitReview.tex @@ -147,6 +147,9 @@ This may be an operational change to reduce the cost of new drugs. \cite{dimasi_ValueImproving_2002} used data on 68 investigational drugs from 10 firms to simulate how reducing -time in development adds to the +time in development reduces the costs of developing drugs. +He estimates that reducing Phase III of clinical trials by one year would +reduce total costs by about 8.9\% and that moving 5\% of clinical trial failures +from phase III to Phase II would reduce out of pocket costs by 5.6\%. \end{document}